Related Experiment Video

Updated: Jan 12, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface

Peng-Cheng Yu1,2, Chen-Xi Yue1, Wen-Zhong Dong1

  • 1Schools of Basic Medicine and Clinical pharmacy, and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|October 31, 2025
PubMed

Insights

Targeting the CD47/SIRPα pathway can treat cancer but risks anemia. A new peptide selectively targets cancer cells, enhancing phagocytosis and delaying tumor growth without causing anemia.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • CD47/SIRPα signaling allows cancer cells to evade macrophage phagocytosis, presenting a therapeutic target.
  • Current CD47-based therapies face safety concerns, notably anemia, limiting their clinical application.

Purpose of the Study:

  • To investigate a CD47-SIRPα immune checkpoint treatment that mitigates anemic side effects.
  • To selectively target the CD47 and integrin αvβ3 costabilization on cancer cells, sparing erythrocytes.

Main Methods:

  • Multiplexed immunofluorescence analysis of 119 clinical breast cancer tissues.
  • Development and application of the engineered peptide PSFL-NK13 to disrupt CD47-integrin αvβ3 interaction.

Main Results:

  • Identified costabilization of CD47 and integrin αvβ3 on cancer cell surfaces, absent in erythrocytes.
  • PSFL-NK13 peptide effectively disrupted this interaction, enhancing macrophage phagocytosis.
  • Demonstrated delayed tumor growth without inducing anemia or promoting angiogenesis.

Conclusions:

  • A novel therapeutic strategy targeting the CD47-integrin αvβ3 interaction offers a safer approach for cancer immunotherapy.
  • This method overcomes anemia side effects associated with traditional CD47 blockade therapies.
  • The findings suggest broader applicability for this strategy across various tumor types.
Keywords:
CD47cancer immunotherapyimmune checkpointintegrin αvβ3peptides

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
945
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.5K
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.9K